Test Directory
 
   
   
  labworks login  
  atlas  
     
line33
  Lifepoint login  
  Lifepoint  
  lpque2  
 
line33
 
     
 
 
     
     
   
announcements
 
   
       
       
   

 

   
     
InfA   Serum Bicarbonate Testing - Important Notice

Read more...
 

 

InfA   Lacosamide, Levetiracetam (Keppra), Topiramate, Zonisamide, Serum Levels
Effective May 4, 2015, to improve turn-around-time, serum therapeutic drug levels for Lacosamide, Levetiracetam (Keppra), Topiramate, and Zonisamide will be performed daily, 7 days a week.
Read more...
     
InfA   HIV-1 Integrase Genotype by Nucleic Acid Sequencing (HIV INT)
Effective March 23, 2015, the Microbiology/Molecular Diagnostics department is adding a DNA sequencing assay for the detection of mutations in the HIV-1 integrase gene that may lead to resistance of Integrase Strand Transfer Inhibitors (INSTIs) antivirals. This test will identify resistance profiles for Raltegravir, Elvitegravir, and Dolutegravir.Read more...

 

   
InfA   Quantitative Opiates, Urine Panel
Effective March 2, 2015, a number of improvements will be made to the Quantitative Opiates Panel on urine specimens.  The lower limit of detection for hydrocodone, oxycodone and fentanyl is improved.  The drug metabolites will also be reported.
Read more...
 
InfA   Quantitative-Confirmatory Urine Drug Tests
Effective March 2, 2015, a number of improvements will be made to Quantitative/Confirmatory Urine Drug tests. The lower limit of detection for hydrocodone, oxycodone and fentanyl is improved.  The drug metabolites will also be reported.  These tests are available for toxicology, pain management, and compliance monitoring.
Read more...
 
InfA  

Meconium Drug Testing
Effective February 23, 2015, testing on meconium specimens for benzodiazepine, barbital, and amphetamine will be available as individual tests.  Due to limitations in specimen quantity, please contact the laboratory prior to ordering if you are considering ordering multiple tests on one meconium specimen.
Read more...

 
InfA   Meconium Drug Panel
Effective February 16, 2015, a new Meconium Drug Panel will be implemented to replace older panels. The new panel will screen for Cocaine and its metabolite, Opiates, Oxycodone, Cannabinoids and Methadone on meconium specimens. Positive results will be confirmed by mass spectrometry.
Read more...
 
InfA   JAK2 NAAT Announcement
Effective January 15, 2015, the Microbiology/Molecular Diagnostics department is adding a Nucleic Acid Amplification Test (NAAT) for the detection of the V617F mutation in the Janus Kinase 2 (JAK2) gene (JAK2 NAAT).
Read more...
   
   
   
     
   
     
   
   
   
 


© 2015 Wisconsin Diagnostic Laboratories. All rights reserved. [site map]